Table 6. Subgroup analysis for OS and RFS.
| Subgroup | Overall survival, median (years) | P value for whole | RFS, median (years) | P value for whole | Inter-subgroup comparison significance |
|---|---|---|---|---|---|
| OX40 expression on TILs | 0.364 | 0.219 | NA | ||
| Positive | 1.72 | 1.41 | |||
| Negative | 3.04 | 2.70 | |||
| OX40 expression on TILs plus PD-L1 expression on tumor | 0.367 | 0.108 | Existed | ||
| Both positive | 1.08 | 0.875 | |||
| Both negative | 3.04 | 2.00 | |||
| Only one positive | 2.77 | 1.8 | |||
| OX40L expression on TILs plus PD-L1 expression on tumor | 0.201 | 0.079 | Existed | ||
| Both positive | 0.9 | 1.30 | |||
| Both negative | 3.28 | 3.26 | |||
| OX40 or PD-L1 positive | 1.49 | 2.35 | |||
| OX40 expression on TILs plus staging | 0.0001 | 0.0001 | Existed | ||
| Stage IA and OX40+ | 3.13 | 1.90 | |||
| Stage IA and OX40− | 4.90 | 4.90 | |||
| Stage IB and OX40+ | 0.85 | 0.65 | |||
| Stage IB and OX40− | 0.75 | 0.63 | |||
| OX40 expression on TILs plus staging plus PD-L1 expression | 0.0001 | 0.0001 | Existed | ||
| Stage IA and both positive | 3.13 | 1.03 | |||
| Stage IA and both negative | 3.50 | 4.903 | |||
| Stage IA and OX40 or PD-L1 positive | 3.25 | 3.08 | |||
| Stage IB and both positive | 1.00 | 0.85 | |||
| Stage IB and both negative | 0.83 | 0.68 | |||
| Stage IB and OX40 or PD-L1 positive | 0.63 | 0.53 | |||
| OX40 expression plus pathology types | 0.306 | 0.2 | Existed | ||
| Adenocarcinoma plus OX40 positive | 5.00 | 1.85 | |||
| Adenocarcinoma plus OX40 negative | 3.21 | 2.93 | |||
| Non-adenocarcinoma plus OX40 positive | 1.50 | 1.30 | |||
| Non-adenocarcinoma plus OX40 negative | 2.95 | 1.8167 |
OS, overall survival; RFS, recurrence-free survival; TILs, tumor infiltrating lymphocytes; PD-L1, program death-ligand 1.